Resverlogix Announces Voting Results From the 2023 Meeting of Shareholders
Resverlogix Announces Voting Results From the 2023 Meeting of Shareholders
Calgary, Alberta--(Newsfile Corp. - June 20, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Corporation") today held its Annual Meeting of Shareholders (the "Meeting") in Calgary, Alberta.
加拿大阿爾伯塔省卡爾加裡-(Newsfile Corp.-2023年6月20日)-Resverlogix Corp.(多倫多證券交易所股票代碼：RVX)(以下簡稱“Resverlogix”，或“公司”)今天在阿爾伯塔省卡爾加裡召開年度股東大會(以下簡稱“股東大會”)。
During business proceedings at the Meeting, shareholders elected five (5) Board members until the next annual meeting. The voting results of shares represented at the Meeting for individual directors were as follows:
在會議的業務程式中，股東選舉了五(5)名董事會成員，直至下一次年度會議。個別董事代表出席會議的股份表決結果如下：
| Votes For | Votes Withheld | Percent For | Percent Withheld | |
| Donald J. McCaffrey | 122,884,287 | 11,547,550 | 91.41% | 8.59% |
| Shawn Lu | 123,340,266 | 11,091,571 | 91.75% | 8.25% |
| Kelly McNeill | 127,204,762 | 7,227,075 | 94.62% | 5.38% |
| Siu Lun (Dicky) To | 127,856,904 | 6,574,933 | 95.11% | 4.89% |
| Kenneth Zuerblis | 129,096,743 | 5,335,094 | 96.03% | 3.97% |
| 投票贊成 | 扣留的選票 | 百分比為 | 扣繳百分比 | |
| 唐納德·J·麥卡弗裡 | 122,884,287 | 11,547,550 | 91.41% | 8.59% |
| 肖恩·Lu | 123,340,266 | 11091571 | 91.75% | 8.25% |
| 凱利·麥克尼爾 | 127,204,762 | 7,227,075 | 94.62% | 5.38% |
| 蕭倫(迪奇)至 | 127,856,904 | 6574,933 | 95.11% | 4.89% |
| 肯尼斯·祖爾布利斯 | 129,096,743 | 5,335,094 | 96.03% | 3.97% |
Resverlogix shareholders approved all resolutions outlined in the Notice of Meeting and Management Information Circular dated May 10, 2023 (the "Information Circular"). The Information Circular is available on SEDAR at , and on the Resverlogix website at .
Resverlogix股東批准了日期為2023年5月10日的會議通知和管理層資訊通告(“資訊通告”)中概述的所有決議。《資訊通報》可在SEDAR和Resverlogix網站上查閱。
A webcast archive of the executive presentation portion of the Meeting will be available HERE.
會議執行演示文稿部分的網路直播檔案將在此處提供。
About Resverlogix
關於Resverlogix
Founded in 2001, Resverlogix is a Calgary-based, late-stage, biotechnology company and the world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.
Resverlogix成立於2001年，是一家總部設在卡爾加裡的晚期生物技術公司，是表觀遺傳學領域的世界領先者，目標是為慢性病患者開發一流的治療方法。
Our new class of epigenetic therapies are designed to regulate the expression of disease-causing genes. We aim to improve patients' lives by restoring biological functions - altered by serious illnesses such as cardiovascular disease - back to a healthier state.
我們的新型表觀遺傳療法旨在調節致病基因的表達。我們的目標是通過將因心血管疾病等嚴重疾病而改變的生物功能恢復到更健康的狀態來改善患者的生活。
The Company's clinical program is focused on evaluating our lead candidate apabetalone for the treatment of cardiovascular disease and associated comorbidities, and post COVID-19 conditions.
該公司的臨床計劃側重於評估我們治療心血管疾病和相關合並症以及新冠肺炎後遺症的主要候選藥物阿帕貝酮。
Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX). Follow us:
Resverlogix普通股在多倫多證券交易所(多倫多證券交易所市場代碼：RVX)交易。跟我們來：
- Twitter: @Resverlogix_RVX
- LinkedIn:
- 推特：@Resverlogix_rvx
- LinkedIn：
For further information please contact:
欲瞭解更多資訊，請聯繫：
Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
投資者關係
電子郵件：ir@resverlogix.com
電話：403-254-9252
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。